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Abstract
Background: High carbohydrate antigen 125 (CA-125) level was reported to be associated with some cardiac
dysfunctions, such as chronic heart failure, but the relationship between CA-125 level and coronary heart disease
(CHD) risk remains unclear. The aim of this study was to explore the potential association in a Chinese older
population.
Methods: In a population-based case-control study conducted in a Chinese older population, serum CA-125 levels
were measured in 1177 diagnosed CHD patients and 3531 age and sex matched control subjects without CHD.
Results: Serum CA-125 level was significantly higher in CHD patients than controls (P < 0.001) with adjustment for
age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication
history and family history of CHD and myocardial infarction. CHD risk was doubled (OR: 2.10, 95%CI: 1.69-2.60)
among subjects in the highest quartile compared to those in the lowest quartile of CA-125 level (Ptrend < 0.001).
Furthermore, CA-125 levels were associated with CHD risks in subjects with age over 60 years (OR: 2.19, 95%CI:
1.75-2.73), current smokers (OR: 2.29, 95%CI: 1.50-3.49), current drinkers (OR: 2.35, 95%CI: 1.57-3.53) and
subjects with hypertension (OR: 2.04, 95%CI: 1.71-2.43).
Conclusions: Elevated serum CA-125 level might be associated with increased risk of coronary heart disease in the
Chinese older population. Further investigations are needed to identify the possible biological role of CA-125 in CHD
development in the future.
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Introduction
CA-125 (Carbohydrate antigen 125) is a well-established
tumor marker to monitor the efficacy of ovarian cancer therapy
and early detect its recurrence [1]. But it is also elevated in
both ovarian and non-ovarian diseases, malignant and non-
malignant conditions [2]. Interestingly, there are evidences
which showed that, CA-125 could be secreted from mesothelial
cells as well as tumoural origin tissue [3,4]. Recent studies
have also demonstrated that serum CA-125 level was
significantly elevated in chronic heart failure patients [5-9].
Furthermore, increasing evidences have indicated that high
serum CA-125 levels were associated with risk of hypertrophic
cardiomyopathy, pseudoaneurysm of the left ventricular lateral
wall, cardiac angiosarcoma, pericardial tamponade, infective
perimyocarditis and atrial fibrillation [10-15]. However, few
studies have investigated whether the higher concentration of
serum CA-125 is associated with the increased risk of coronary
heart disease (CHD) or not until now.
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Coronary heart disease (CHD) is a condition in which there is
an inadequate supply of blood and oxygen to a portion of the
myocardium; it typically occurs when there is an imbalance
between myocardial oxygen supply and demand. It is one of
the leading causes of mortality and disability in both
industrialized and developing countries [16-18]. It was
estimated that heart disease and stroke are projected to be the
single leading cause of death by 2030 [19]. CHD is a multi-
factorial disease and the underlying mechanisms of CHD have
not been well elucidated clearly. Inflammation is considered to
play an important role in the development of atherosclerosis
[20,21]. Systemic inflammation could enhance atherogenesis
and inflammatory components could drive the formation,
progression and rupture of atherosclerotic plaques for
inflammation could promote loss of endothelium, the hallmark
of superficial erosion [22-25]. Previous studies have also found
that CA-125 could be produced by mesothelial cells as a
consequence of inflammation, stasis or other stimulatory
mechanisms in patients with heart failure [5,6,9,26]. Recently, a
small case-control study also suggested inflammation and
cytokine levels may be responsible for CA-125 production and
release [27]. Given this evidence, it is reasonable to
hypothesize that there may be a potential association between
serum CA-125 level and CHD risk.
Here, we performed a large population-based case-control
study to explore the association between serum CA-125 level
and the CHD risk in Chinese older population, which was
based on Dongfeng-Tongji cohort study of retired workers in
Shiyan, Hubei province, China.
Methods
Ethics statement
Ethical approval was obtained from the Medical Ethics
Committee of the School of Public Health, Tongji Medical
College, Huazhong University of Science and Technology.
Study population and design
We used data from Dongfeng-Tongji cohort (DFTJ cohort)
study of retired workers, which was described in detail
elsewhere [28]. Briefly, this cohort was launched in 2008
among retirees of Dongfeng Motor Corporation (DMC) in
Shiyan City, Hubei province, China. For the current study, we
included 1177 documented CHD cases and 3531frequency-
matched (by age and gender) controls between September
2008 and June 2010. CHD was confirmed on the basis of the
most recent international guidelines: a combination of classical
symptoms with positive results from 12-lead electrocardiograph
(ECG), cardiac enzymes, functional or stress test, or coronary
angiography using standard Judkins techniques (significant
coronary artery stenoses≥50% in at least one major coronary
artery) [29]. A total of 55.73% (656) CHD cases underwent
coronary angiography. Nonfatal myocardial infarction was
diagnosed by a development of pathologic Q waves on serial
ECG, elevations of cardiac enzyme values, or medical records
for clinical symptoms and signs. 210 of CHD cases were
diagnosed as MI according to their medical record.
Controls were randomly selected from retired employees
employed in the same DFTJ cohort on the basis of medical
history, clinical examinations, electrocardiography and face-to-
face inquiry at admission. None of them had abnormalities of
ECG or diagnostic evidence of CHD. Hypertension was defined
as systolic/ diastolic blood pressure≥140/90mmHg in at least
two measurements, or current use of anti-hypertensive
medicine for the most recent 2 weeks, or a previous diagnosis
of hypertension by a clinician. Diabetes mellitus (DM) was
defined by the WHO criteria [30]: fasting blood glucose (FBG)
≥7mmol/L or a 2 hour postprandial plasma glucose
≥11.1mmol/L, or a prescription history of antidiabetic
medications, including oral antidiabetics, incretin products, and
insulin during the most previous two weeks, or a previous
diagnosis of DM. Dyslipidemia was diagnosed as total
cholesterol (TC) concentration≥5.72 mmol/L or triglyceride (TG)
concentration ≥1.70 mmol/L or high-density lipoprotein
cholesterol (HDL-C) concentration≤0.91mmol/L, or use
medicine of dyslipidemia during the previous two weeks, or a
positive history for dyslipidemia. All chronic diseases were
verified through medical record reviews.
Subjects with a history of congenital heart disease, chronic
heart failure, recent acute coronary syndrome (< 6 months),
vascular disease, valvular disease, cardiomyopathy and
neoplastic diseases and cancers were excluded through
medical record review based on clinical symptoms, physical
examination, electrocardiogram and chest X-ray.
After obtained written informed consent from every
participant, a semi-structural questionnaire was used to collect
baseline information by trained interviewers during face-to-face
interviews. The medical examination was performed at the
same time. Demographic information, socio-economic status,
family and personal disease histories, medication history in
recent two weeks, alcohol use and smoking consumption were
also inquired in the questionnaire.
Educational levels were categorized as low (primary school
or illiteracy), medium (junior high school) and high (senior high
school, university or college or higher). Body mass index (BMI)
was calculated as weight in kilograms divided by height in
meters squared.
Laboratory measurement
After an overnight fast, five milliliters of fasting blood was
drawn from all subjects with a vacuum coagulation tube for
serum in the morning. We measured the serum CA-125 level
with the ARCHITECT Ci8200 automatic analyzer
(ABBOTT Laboratories. Abbott Park, Illinois, U.S.A.) using
the Abbott Diagnostics reagents according to the
manufacturer’s instructions at Dongfeng Central Hospital’s
laboratory. The method used by the ARCITECT Ci8200
platform for serum CA-125 levels measurement is microparticle
chemiluminescent immunoassay (CMIA).The intra-assay
coefficients of variation were 5.50% for CA-125. Blood glucose
and blood lipids (including TC, TG and HDL-C) measurements
were described in our previous study [28].
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Statistical analysis
Characteristics of study subjects are presented as mean
(SD) for continuous variables and as percentages for
categorical data. All continuous variables were tested for
normal distribution with the Kolmogorov-Smirnov test. For
serum CA-125 levels, the cut off values for division of data into
concentration categories were based on the distribution in
controls. Continuous variables were analyzed by 2-tailed t tests
for normal distributions and the Mann-Whitney U test for
nonparametric distributions. Categorical data were evaluated
by Chi-square test as appropriate. Odds ratios and 95%
confident intervals were estimated by logistic regression with
and without adjustment for age, gender, smoking, drinking,
BMI, physical activity, hypertension, dyslipidemia, diabetes
mellitus, medication history and family history of CHD and
myocardial infarction. All tests were two-sided and α < 0.05
was considered statistically significant. Analyses were
performed using SPSS software (version 12.0; SPSS Inc.,
Chicago, IL, USA).
Results
Characteristics of study population
The demographic characteristics of the study population are
presented in Table 1. When compared with the controls,
smoking (P < 0.001) and higher BMI (P < 0.001) were more
common in cases while lower DBP (P < 0.001) and less
drinking (P < 0.001) were found among cases. Total cholesterol
(TC) and high-density lipoprotein cholesterol (HDL-C) were
lower in CHD cases than controls (P < 0.001). As expected,
CHD patients were more likely to have hypertension,
dyslipidemia and diabetes mellitus (P < 0.001, respectively).
Pharmacological drugs (antibiotics, anticoagulant, anti-
hypertensive and hypoglycemic drugs) were more often used in
cases (P < 0.001, respectively). Median and range of CA-125
level were 7.60 U/ml (3.50-11.40 U/ml) in cases and 5.54 U/ml
(1.31-9.90 U/ml) in controls. Serum CA-125 level was
significantly higher in CHD cases than that in controls (P <
0.001).
Serum CA-125 level and CHD risk
Analyses of CA-125 level in quartiles (Table 2) showed that
the risk of CHD was doubled (OR: 2.10, 95%CI: 1.69-2.60) in
the highest quartile of CA-125 level (CA-125≥9.90U/ml)
compared to those in the lowest quartile (CA-125≤1.31U/ml).
The risk among those in the third quartile (OR: 2.08) of CA-125
levels was similar to those in the fourth quartile (OR: 2.10).
These two groups therefore were combined into a group as
“high” CA-125 level and similarly, the first and the second
quartiles were combined into the “low” CA-125 level group for
further stratified analyses.
As shown in Table 3, the association between CA-125 level
and CHD risk tended to be stronger among older persons (OR:
2.19, 95%CI: 1.75-2.73), males (OR: 2.07, 95%CI: 1.67-2.56)
and overweight (OR: 2.03, 95%CI: 1.62-2.55) after adjustment
for age, gender, smoking, drinking, BMI, physical activity,
hypertension, dyslipidemia, diabetes mellitus, medication
history and family history of CHD and myocardial infarction.
The CHD risk was inclined to be stronger among current
smokers (OR: 2.29, 95%CI: 1.50-3.49), current drinkers (OR:
Table 1. Demographic characteristics of study subjects.
Demographic and risk factors Cases (n = 1177) Controls (n = 3531) P-value
Age   0.995
< 60 106 (9.01) 319 (9.03)  
60- 566 (48.09) 1703 (48.23)  
≥ 70 505 (42.91) 1509 (42.74)  
Gender   0.93
Male 616 (52.34) 1853 (52.48)  
Female 561 (47.66) 1678 (47.52)  
Education levels†   0.65
Low 395 (33.85) 1149 (32.79)  
Medium 402(34.45) 1194 (34.08)  
High 370 (31.71) 1161 (33.13)  
BMI (kg / m2)   < 0.001
< 23.9 371 (32.04) 1605 (46.44)  
24- 552 (47.67) 1387 (40.13)  
≥ 28 235 (20.29) 464 (13.43)  
Physical activity 1043 (88.62) 3198 (90.57) 0.052
Blood pressure(mmHg)    
SBP 131.91 ± 17.36 131.29 ± 18.25 0.31
DBP 76.15 ± 10.47 77.35 ± 10.47 0.001
TC(mmol/L) 4.89 ± 1.14 5.21 ± 0.97 < 0.001
TG (mmol/L) 1.49 ± 0.95 1.43 ± 1.05 0.12
HDL (mmol/L) 1.34 ± 0.36 1.44 ± 0.41 < 0.001
Smoking status   < 0.001
Current 148 (12.60) 693 (19.73)  
Former 277 (23.57) 415 (11.81)  
Never 750 (63.83) 2405 (68.46)  
Drinking status   < 0.001
Current 170 (14.46) 788 (22.32)  
Former 133 (11.31) 159 (4.50)  
Never 873 (74.23) 2583 (73.17)  
Medication history    
Antibiotics 114 (9.69) 177 (5.01) < 0.001
Anticoagulant 682 (57.94) 359 (10.17) < 0.001
Anti-hypertensive medication 770 (65.42) 965 (27.33) < 0.001
Hypoglycemic medication 257 (21.84) 346 (9.80) < 0.001
Disease History    
Hypertension 942 (80.03) 1919 (54.35) < 0.001
Diabetes mellitus 371 (31.52) 664 (18.80) < 0.001
Dyslipidemia 905 (76.89) 1932 (54.72) < 0.001
Family history of disease    
Coronary heart disease 183 (15.55) 186 (5.27) < 0.001
Myocardial infarction 38 (3.29) 32 (0.92) < 0.001
CA-125 level (U/ml) 7.60 (3.50-11.40) 5.54 (1.31-9.90) < 0.001*
Data are presented as number (percentage) or mean ± SD unless noted otherwise.
CA-125 is presented as median (25th- 75th quartile). P values were calculated
using 2-tailed t tests or Chi-square test.
P*value was obtained using the Mann-Whitney U test.
Education levels†: Low, Primary school or illiteracy; Medium, Junior high school;
High, Senior high school, university or college or higher.
Abbreviations: TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein.
doi: 10.1371/journal.pone.0081328.t001
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2.35, 95%CI: 1.57-3.53) and persons with hypertension (OR:
2.04, 95%CI: 1.71-2.43), without diabetes mellitus (OR: 2.09,
95%CI: 1.75-2.50) and dyslipidemia (OR: 2.21, 95%CI:
1.66-2.95).
We further analyzed serum CA-125 level and myocardial
infarction (MI) risk in our population (Table S1), of the 210 CHD
patients having MI, higher level of CA-125 was related to
higher MI risk in a dose-responsive manner with adjustment for
age, gender, smoking, drinking, BMI, physical activity,
hypertension, dyslipidemia, diabetes mellitus, medication
history and family history of CHD and myocardial infarction.
CA-125 level and the severity of coronary artery
stenoses in CHD
We divided the 1177 CHD cases into two groups: CHD
accompanying with MI (210, Table S1) and CHD without MI
(967, Table S2), and then compared the two groups with
controls (3531) respectively, the adjusted OR of CHD patients
accompanying with MI in highest quartile of CA-125 level was
2.76 (95%CI: 1.73-4.41, P < 0.001), and that of CHD patients
without MI was 2.02 (95%CI: 1.61-2.54, P < 0.001) after
adjustment for age, gender, smoking, drinking, BMI, physical
activity, hypertension, dyslipidemia, diabetes mellitus,
medication history and family history of CHD and myocardial
infarction.
Relation of CHD risk factors and serum CA-125 level
among controls
Serum CA-125 level of controls ascended substantially with
increasing age (Ptrend < 0.001; Table 4). Males tended to have
higher serum CA-125 level than females (P = 0.015). Smokers
had significantly higher CA-125 level than nonsmokers (P =
0.04). Controls with hypertension have significantly lower
serum CA-125 level than those without hypertension (P =
0.001). Contrary results were found in controls with and without
diabetes mellitus (P < 0.001). Controls taken hypoglycemic
Table 2. The association between CA-125 level and CHD
risk in Chinese older population.
Quartile
CA-125 level
(U/ml)
Cases, n
(%)
Controls, n
(%) OR (95% CI) OR‡ (95% CI)
First ≤ 1.31 191(16.23)
881
(24.95) 1.00 1.00
Second 1.31-5.54 215(18.27)
884
(25.04)
1.12
(0.90-1.39)
1.11
(0.87-1.40)
Third 5.54-9.90 380(32.29)
877
(24.84)
2.00
(1.64-2.44)
2.08
(1.67-2.58)
Fourth ≥ 9.90 391(33.22)
889
(25.18)
2.03
(1.67-2.47)
2.10
(1.69-2.60)
    Ptrend< 0.001 Ptrend< 0.001
OR: Crude OR. OR‡: Adjusted for age, gender, smoking, drinking, BMI, physical
activity, hypertension, dyslipidemia, diabetes mellitus, medication history and
family history of CHD and myocardial infarction.
doi: 10.1371/journal.pone.0081328.t002
drugs tend to have significantly higher level of CA-125 (P =
0.03).
Table 3. Associations between CA-125 level and CHD risk
by subgroups.
Risk factors Level§ Cases  Controls  
Crude OR (95%
CI)  OR# (95% CI)
Age      
< 60 Low 51 163 1.00 1.00
 High 55 156 1.13 (0.73-1.75) 1.44 (0.83-2.51)
60- Low 201 895 1.00 1.00
 High 365 808 2.01 (1.65-2.45) 2.19 (1.75-2.73)
≥ 70 Low 154 707 1.00 1.00
 High 351 802 2.01 (1.62-2.49) 2.00 (1.58-2.53)
Gender      
Male Low 198 898 1.00 1.00
 High 418 955 1.99 (1.64-2.41) 2.07 (1.67-2.56)
Female Low 208 867 1.00 1.00
 High 353 811 1.81 (1.49-2.21) 1.96 (1.58-2.44)
BMI      
< 23.9 Low 127 807 1.00 1.00
 High 244 798 1.94 (1.54-2.46) 2.00 (1.55-2.58)
24- Low 189 692 1.00 1.00
 High 363 695 1.91 (1.56-2.35) 2.03 (1.62-2.55)
≥ 28 Low 87 246 1.00 1.00
 High 156 245 1.80 (1.31-2.47) 1.93 (1.34-2.78)
Smoking status      
Current Low 50 360 1.00 1.00
 High 98 333 2.12 (1.46-3.07) 2.29 (1.50-3.49)
Former Low 90 188 1.00 1.00
 High 187 227 1.72 (1.25-2.36) 1.93 (1.34-2.77)
Never Low 264 1207 1.00 1.00
 High 486 1198 1.86 (1.57-2.20) 1.93 (1.60-2.33)
Drinking status      
Current Low 49 399 1.00 1.00
 High 121 389 2.53 (1.77-3.63) 2.35 (1.57-3.53)
Former Low 51 63 1.00 1.00
 High 82 96 1.06 (0.66-1.69) 1.21 (0.69-2.12)
Never Low 305 1303 1.00 1.00
 High 568 1280 1.90 (1.62-2.22) 2.05 (1.72-2.45)
Disease history      
Hypertension      
Yes Low 330 1009 1.00 1.00
 High 612 910 2.06 (1.75-2.42) 2.04 (1.71-2.43)
No Low 76 756 1.00 1.00
 High 159 856 1.85 (1.38-2.47) 1.91 (1.41-2.60)
Dyslipidemia      
Yes Low 314 958 1.00 1.00
 High 591 974 1.85 (1.57-2.18) 1.91 (1.59-2.28)
No Low 92 807 1.00 1.00
 High 180 792 1.99 (1.52-2.61) 2.21 (1.66-2.95)
Diabetes mellitus      
Yes Low 123 284 1.00 1.00
 High 248 380 1.51 (1.16-1.97) 1.59 (1.17-2.15)
No Low 283 1481 1.00 1.00
 High 523 1386 1.98 (1.68-2.32) 2.09 (1.75-2.50)
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Discussion
In this population-based case-control study, we investigated
the association between serum CA-125 level and the risk of
CHD in a large Chinese older population for the first time. We
observed that the elevated serum CA-125 level was associated
with a higher risk of CHD, and such associations were also
evident in older individuals, males, current smokers and
drinkers, overweight individuals, and those who had
hypertension.
In early time, serum CA-125 was found to be related to
diastolic and systolic parameters, ejection fraction and
myocardial performance index in patients with chronic HF [31].
Subsequently, elevated CA-125 level has also been observed
in other cardiac pathologies such as aortic stenosis, mitral
stenosis, mitral valve endocarditis, acute myocardial infarction
[32-36]. However, in stark contrast, little data has been
published concerning the association of the concentration of
serum CA-125 and CHD risk until now.
As to the possible mechanisms involved in increased CA-125
level observed in HF, De Gennaro et al. suggested that
haemodynamic abnormalities and inflammatory cytokines may
play significant roles in the development of atherosclerosis and
its complications [37]. A few later studies have also
demonstrated that CA-125 is expressed in different tissues
derived from coelomic epithelium in response to various stimuli,
including mechanical stress and inflammatory stimuli [38-41].
Furthermore, under normal circumstances, mesothelial cells
could maintain a steady-state with proliferation balanced by cell
death. However, such balance is disrupted when mesothelial
cells are exposed to mechanical stress and inflammatory
stimuli in the early phase of atherosclerosis. On the one hand,
mesothelial cells might synthesize more hyaluronan and
cytoplasmic fibers to defense the cellular injury and death
[42,43]. Vitro experiments have demonstrated that the
secretion of CA-125 could be enhanced by the inflammatory
cytokines [44]. So inflammatory may be responsible for serum
CA-125 role in CHD development. Our findings suggested that
serum CA-125 was related to some inflammatory related
status, such as smoking, hypertension and diabetes mellitus,
may act as an evidence to support this hypothesis.
In our study, CA-125 level-associated CHD risks were higher
in subjects aged over 60 years, overweight individuals,
cigarette smoke and hypertension. The similar results have
been found in the PLCO (Prostate, Lung, Colorectal and
Ovarian Cancer) screening trial [45] except for subjects with
hypertension. These factors may damage the endothelium and
lead to the subsequent inflammatory reactions in the vascular
wall, which in turn increases the production of primary
Table 3 (continued).
Low§: the first and second quartiles; High: the third and fourth quartiles.
OR#: Adjusted for age, gender, smoking, drinking, BMI, physical activity,
hypertension, dyslipidemia, diabetes mellitus, medication history and family history
of CHD and myocardial infarction.
doi: 10.1371/journal.pone.0081328.t003
proinflammatory cytokines [46]. The association of higher
CA-125 level with higher CHD risk in older age could possibly
be a consequence of aging processes at the cellular and
immunological level [45]. Cigarette smoke is a major risk factor
for CHD and produces a chronic inflammatory state that
contributes to the atherogenic disease processes and elevates
levels of biomarkers of inflammation. Besides, this chronic
Table 4. Relation between CHD risk factors and CA-125
level among controls.
Demographic and risk
factors  N (n = 3531)   CA-125, mean ± SD (U/ml)   P-value
Age   0.001
< 60 319 6.90 ± 8.34  
60- 1703 6.25 ± 6.99  
≥ 70 1509 7.04 ± 6.64  
Gender   0.01
Male 1853 6.96 ± 7.69  
Female 1678 6.30 ± 6.11  
BMI   0.07
< 23.9 1605 6.55 ± 7.00  
24- 1387 6.65 ± 7.29  
≥ 28 464 7.03 ± 6.20  
Medication history    
Antibiotics   0.93
Yes 177 6.74 ± 6.96  
No 3354 6.64 ± 6.99  
Anticoagulant   0.07
Yes 359 7.10 ± 6.21  
No 3172 6.60 ± 7.07  
Anti-hypertensive
medication   0.31
Yes 965 6.68 ± 6.00  
No 2566 6.63 ± 7.33  
Hypoglycemic medication   0.03
Yes 346 7.17 ± 6.08  
No 3185 6.59 ± 7.08  
Smoking status   0.04
Current 693 6.69 ± 7.54  
Former 415 7.62 ± 9.84  
Never 2405 6.47 ± 6.19  
Drinking status   0.11
Current 788 6.80 ± 7.24  
Former 159 8.37 ± 13.75  
Never 2583 6.49 ± 6.24  
Disease History    
Hypertension   0.001
Yes 1919 6.36 ± 6.44  
No 1612 6.99 ± 7.57  
Dyslipidemia   > 0.05
Yes 1932 6.84 ± 7.41  
No 1599 6.40 ± 6.44  
Diabetes mellitus   < 0.001
Yes 664 7.41 ± 6.26  
No 2867 6.47 ± 7.14  
doi: 10.1371/journal.pone.0081328.t004
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state of inflammation might be directly related to subsequent
elevated risk for cardiovascular diseases and has detrimental
effects on the metabolism and function of innate immune cells
[47,48]. The plausibility is supported by our observation that
among controls smokers tended to have higher level of serum
CA-125 than nonsmokers.
An inverse correlation between CA-125 level and metabolic
syndrome was recently reported in a study including 12,196
healthy Korean women [49]. Similar results have been also
found in the present study. For example, controls with
hypertension had significantly lower serum CA-125 level than
those without hypertension. While conflicting findings showed
that serum CA-125 levels were associated with lower risks of
CHD in patients with dyslipdemia and diabetes mellitus after
adjustment with confounding factors. That may be due to the
different doses and/or the duration of the medicines they taken.
However, the precise mechanisms should be investigated in
future prospective studies.
In terms of limitations, the current case-control design limits
the causal interpretation of the relationship between serum
CA-125 level and the risk of coronary heart disease because
the blood samples were collected from subjects having CHD
events. Another limitation is that some CHD cases took
multiple medications, which acted as a confounding factor
when we analyzed the relationship between CA-125 level and
CHD risk by subgroups. Thus, such findings need to be
validated by future large prospective investigations.
Furthermore, the role of unmeasured or residual confounding
could not be ignored although we have adjusted for a wide
range of CHD risk factors. Nevertheless, this is the first study to
examine the association between serum CA-125 level and the
risk of CHD in a large Chinese older population. Secondly, the
sample size is considerable, which allows us to investigate the
association between increased CA-125 level and CHD risk.
Conclusions
In summary, our findings suggested that higher serum
CA-125 level might be associated with a significantly increased
risk of CHD in Chinese older population. Future prospective
studies should be motivated by this finding to explore the
precise mechanisms.
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